Latest News

Ahead of the e-Therapeutics plc Annual General Meeting on 11 June, the acting Chairman and CEO, Professor Malcolm Young, commented on accelerated progress across the business over the last 12 months. The press release can be viewed here. 

 

The results of the AGM have been announced here.


The Network Pharmacology Company

e-Therapeutics is a drug discovery and development company based in Oxford and Newcastle, UK. The Company is a pioneer of network pharmacology, a distinctive new approach to the discovery of medicines.  

It has a clinical pipeline of two drugs, ETS2101, which is in phase I trials for cancer, and ETS6103, which is in phase II development for depression

 

e-Therapeutics is listed on AIM with the ticker symbol ETX

 

Progress in ETS2101 Phase Ib Study

e-Therapeutics has announced that the first patient has been enrolled into its phase 1b programme for its cancer drug, ETS2101.  More details available here.

Full year results

e-Therapeutics annual report and accounts for the year ended 31 January 2015 has been released.  It can be viewed here.

e-Therapeutics' Impact is rated World Class

The impact of e-Therapeutics plc (AIM: ETX)  drug discovery activities has been rated World Class by the UK's National Research and Impact Assessment exercise.  More details available here.